1. Home
  2. SUPN

SUPN

Supernus Pharmaceuticals Inc.

Logo Supernus Pharmaceuticals Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-17-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Founded: 2005 Country:
United States
United States
Employees: N/A City: ROCKVILLE
Market Cap: 1.7B IPO Year: 2012
Target Price: $41.00 AVG Volume (30 days): 402.6K
Analyst Decision: Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 0.02 EPS Growth: -98.08
52 Week Low/High: $21.99 - $39.09 Next Earning Date: 05-07-2024
Revenue: $607,521,000 Revenue Growth: -8.95%
Revenue Growth (this year): 1.28% Revenue Growth (next year): 3.07%

Share on Social Networks: